September 2018

Impact of Goals of Care on Resource Use at End of Life

September 13, 2018

Partner Perspectives

Researchers exam­ined whether there were differences in resource use at end of life between patients with advanced cancer who identified goals of care focused heavily upon survival versus those who identified goals of care heavily focused on quality of life.

Glutaminase Inhibitor That Starves Tumor Cells May Improve Survival in Metastatic RCC

September 11, 2018

Clinical Trials in Progress

A novel glutaminase inhibitor, CB-839, may provide a survival benefit in combination with cabozantinib (Cabometyx) by cutting off the energy supply to tumor cells in patients with metastatic renal cell carcinoma (RCC).

Novel RET Inhibitor Tested in Patients With NSCLC, MTC

September 11, 2018

Clinical Trials in Progress

The phase I open-label LIBRETTO-001 clinical trial is currently testing LOXO-292, an oral small molecule inhibitor of RET signaling, to improve outcomes in patients with RET fusion–positive non–small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and other tumors with increased RET activity.

JAK Inhibition in Myelofibrosis Treatment May Cause Aggressive Lymphoma in Small Percentage of Patients

September 03, 2018

Adverse Events Report

Although JAK inhibitors are a proven effective treatment for patients with myelofibrosis, a type of myeloproliferative neoplasm (MPN), they may come with a severe downside; in particular, a 16-fold increase in the chance of developing a B-cell lymphoma, according to recent research published in the journal Blood.